This activity has been designed to meet the educational needs of managed care decision-makers (health system/managed care pharmacists, specialty pharmacists, hospital pharmacists, medical directors, managed care VPs, CPOs and health plan administrators) involved in the care of patients with rare/orphan diseases.
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s)
(0.15 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - 0809-9999-16-409-H01-P)
Type of Activity: Knowledge
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and DKBmed. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.Credit Designation
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
After completing this activity, the participant should be better able to:
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|James T. Kenney, RPh, MBA||Has no real or apparent conflict of interest|
|Patrick Flume, MD||Consulting fees: Bayer Healthcare AG, Insmed, Vertex Pharmaceuticals, Raptor Pharmaceuticals, Savara Pharma
Contracted Research: Bayer Healthcare AG, Cystic Fibrosis Foundation, Gilead Sciences, Hill-Rom Services, Insmed, Nivalis Therapeutics, National Institutes of Health, Novartis, Pharmaxis Limited, Savara Pharma, Vertex Pharmaceuticals
|Mary B. Dwight||Has no real or apparent conflict of interest|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following DKB planners and managers, Dean Beals, Stan Pogroszewski, and Rachel Deerr hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participation in this CME activity. To receive credit, participants must 1) read the learning objectives and disclosure statements, 2) complete the educational activity and 3) complete the post-test and activity evaluation form, including the certificate information section. Physicians and pharmacists must attest to the amount of time they spent on the activity.
Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
HARDWARE & SOFTWARE REQUIREMENTS
PC: Internet Explorer (v9 or greater), Chrome or Firefox
Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.